Samsung Bioepis has entered a new global agreement with Sandoz to develop and commercialise up to five next‑generation ...
Atrogi has dosed the first participants in a human study of its lead candidate ATR‑258, marking a significant step forward for the Stockholm-based biotech as it advances its next‑generation approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results